'Giving and taking': Endothelial and β-cells in the islets of Langerhans

Trends in Endocrinology and Metabolism

Volumn 21, Issue 8, 2010, Pages 457-463

  Eberhard, Daniel ^a   Kragl, Martin ^a   Lammert, Eckhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

BLOOD VESSEL; BODY GROWTH; CELL INTERACTION; CELL STRUCTURE; ENDOTHELIUM CELL; HUMAN; HYDROSTATIC PRESSURE; INSULIN RELEASE; LANGERHANS CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONCOTIC PRESSURE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL COMMUNICATION; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MICROVESSELS; PANCREAS;

EID: 77955272726     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.03.003     Document Type: Review

References (57)

1. Kim A., et al. Islet architecture: a comparative study. Islets 2009, 1:129-136.
2. Cabrera O., et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2334-2339.
3. Kawamori D., et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009, 9:350-361.
4. Eberhard D., Lammert E. The pancreatic beta-cell in the islet and organ community. Curr. Opin. Genet. Dev. 2009, 19:469-475.
5. Mandriota S.J., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001, 20:672-682.
6. Olsson R., Carlsson P.O. The pancreatic islet endothelial cell: emerging roles in islet function and disease. Int. J. Biochem. Cell Biol. 2006, 38:492-497.
7. Nyman L.R., et al. Real-time, multidimensional in vivo imaging used to investigate blood flow in mouse pancreatic islets. J. Clin. Invest. 2008, 118:3790-3797.
8. Ballian N., Brunicardi F.C. Islet vasculature as a regulator of endocrine pancreas function. World J. Surg. 2007, 31:705-714.
9. Speier S., et al. Noninvasive high-resolution in vivo imaging of cell biology in the anterior chamber of the mouse eye. Nat. Protoc. 2008, 3:1278-1286.
10. Takahashi N., et al. Fusion pore dynamics and insulin granule exocytosis in the pancreatic islet. Science 2002, 297:1349-1352.
11. Takahashi N., Kasai H. Exocytic process analyzed with two-photon excitation imaging in endocrine pancreas. Endocr. J. 2007, 54:337-346.
12. Bonal C., Herrera P.L. Genes controlling pancreas ontogeny. Int. J. Dev. Biol. 2008, 52:823-835.
13. Lammert E., et al. Induction of pancreatic differentiation by signals from blood vessels. Science 2001, 294:564-567.
14. Yoshitomi H., Zaret K.S. Endothelial cell interactions initiate dorsal pancreas development by selectively inducing the transcription factor Ptf1a. Development 2004, 131:807-817.
15. Jacquemin P., et al. An endothelial-mesenchymal relay pathway regulates early phases of pancreas development. Dev. Biol. 2006, 290:189-199.
16. Edsbagge J., et al. Vascular function and sphingosine-1-phosphate regulate development of the dorsal pancreatic mesenchyme. Development 2005, 132:1085-1092.
17. Kapa S., et al. Dorsal pancreas agenesis and polysplenia/heterotaxy syndrome: a novel association with aortic coarctation and a review of the literature. J. Pancreas 2007, 8:433-437.
18. Brissova M., et al. Pancreatic islet production of vascular endothelial growth factor-A is essential for islet vascularization, revascularization, and function. Diabetes 2006, 55:2974-2985.
19. Lammert E., et al. Role of VEGF-A in vascularization of pancreatic islets. Curr. Biol. 2003, 13:1070-1074.
20. Jabs N., et al. Reduced insulin secretion and content in VEGF-A deficient mouse pancreatic islets. Exp. Clin. Endocrinol. Diabetes 2008, 116(Suppl. 1):S46-49.
21. Iwashita N., et al. Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia 2007, 50:380-389.
22. Brindle N.P., et al. Signaling and functions of angiopoietin-1 in vascular protection. Circ. Res. 2006, 98:1014-1023.
23. Su D., et al. Angiopoietin-1 production in islets improves islet engraftment and protects islets from cytokine-induced apoptosis. Diabetes 2007, 56:2274-2283.
24. Nikolova G., et al. The vascular basement membrane: a niche for insulin gene expression and β cell proliferation. Dev. Cell 2006, 10:397-405.
25. Jiang F.X., et al. Laminin-1 promotes differentiation of fetal mouse pancreatic beta-cells. Diabetes 1999, 48:722-730.
26. Crawford L.A., et al. Connective tissue growth factor (CTGF) inactivation leads to defects in islet cell lineage allocation and beta-cell proliferation during embryogenesis. Mol. Endocrinol. 2009, 23:324-336.
27. Sachdeva M.M., Stoffers D.A. Meeting the demand for insulin: molecular mechanisms of adaptive postnatal β-cell mass expansion. Mol. Endocrinol. 2009, 23:747-758.
28. Johansson M., et al. Perinatal development of the pancreatic islet microvasculature in rats. J. Anat. 2006, 208:191-196.
29. Ham J.N., et al. Exendin-4 normalizes islet vascularity in intrauterine growth restricted rats: potential role of VEGF. Pediatr. Res. 2009, 66:42-46.
30. Kamba T., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H560-576.
31. Toyofuku Y., et al. Normal islet vascularization is dispensable for expansion of beta-cell mass in response to high-fat diet induced insulin resistance. Biochem. Biophys. Res. Commun. 2009, 383:303-307.
32. Postic C., et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 1999, 274:305-315.
33. Jimenez B., et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 2000, 6:41-48.
34. Olerud J., et al. Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes 2008, 57:1870-1877.
35. Crawford S.E., et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998, 93:1159-1170.
36. Johansson M., et al. Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats. Endocrinology 2006, 147:2315-2324.
37. Donath M.Y., et al. Cytokines and beta-cell biology: from concept to clinical translation. Endocr. Rev. 2008, 29:334-350.
38. LeCouter J., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003, 299:890-893.
39. Virtanen I., et al. Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. Diabetologia 2008, 51:1181-1191.
40. Kaido T., et al. Regulation of human beta-cell adhesion, motility, and insulin secretion by collagen IV and its receptor α1β1. J. Biol. Chem. 2004, 279:53762-53769.
41. Clee S.M., et al. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat. Genet. 2006, 38:688-693.
42. Goodarzi M.O., et al. SORCS1: a novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes 2007, 56:1922-1929.
43. Ehses J.A., et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13998-14003.
44. Homo-Delarche F., et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006, 55:1625-1633.
45. Lacraz G., et al. Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS ONE 2009, 4:e6963.
46. Larsen C.M., et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
47. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
48. Li X., et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 2006, 55:2965-2973.
49. Shapiro A.M., et al. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 2006, 355:1318-1330.
50. Mattsson G., et al. Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 2002, 51:1362-1366.
51. Lai Y., et al. Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. Transplantation 2005, 79:1530-1536.
52. Zhang N., et al. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 2004, 53:963-970.
53. Sordi V., et al. Mesenchymal cells appearing in pancreatic tissue culture are bone marrow-derived stem cells with the capacity to improve transplanted islet function. Stem Cells 2010, 28:140-151.
54. Sellaro T.L., et al. Maintenance of hepatic sinusoidal endothelial cell phenotype in vitro using organ-specific extracellular matrix scaffolds. Tissue Eng. 2007, 13:2301-2310.
55. Ott H.C., et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 2008, 14:213-221.
56. Nakamura M., et al. The endocrine pancreas of spontaneously diabetic db/db mice: microangiopathy as revealed by transmission electron microscopy. Diabetes Res. Clin. Pract. 1995, 30:89-100.
57. Favaro E., et al. Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway. Am. J. Pathol. 2008, 173:442-450.